WuXi puts down more roots in Singapore with major new facility

21 March 2024
wuxi_large_new

In Singapore, a modern manufacturing facility is to be built by Chinese contract research, development and manufacturing organization (CRDMO) WuXi Biologics (HK: 2269).

The Hong Kong-listed company has already broken ground on the 13.5-hectare center at the Tuas Biomedical Park, which will eventually host integrated biologics research, development and manufacturing services.

WuXi is now one of the leading players in the contract research and manufacturing sector, inking major deals with companies including  BioNTech (Nasdaq: BNTX) and  GSK (LSE: GSK).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology